宣泰医药：获得注射用硫酸艾沙康唑药品注册证书

Core Viewpoint - XuanTai Pharmaceutical (688247) has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients [1] Group 1 - The company announced the receipt of the drug registration certificate on January 6 [1] - Injectable isavuconazole is specifically approved for treating two serious fungal infections: invasive aspergillosis and invasive mucormycosis [1]